摘要
肿瘤相关静脉血栓栓塞症(cancer-associated venous thromboembolism,CAVTE)是肿瘤患者常见的并发症和死亡原因。因此,如何预防CAVTE的发生受到越来越多的关注。预防性抗凝治疗可以降低肿瘤患者的血栓发生风险,因此需要将患者的获益和不良反应进行充分评估,排除抗凝治疗禁忌后,对血栓高危患者进行预防性的抗凝治疗。
Cancer-associated venous thromboembolism(VTE)is a common complication and cause of death in patients with cancer.Therefore,strategies to prevent the occurrence of VTE have increasingly attracted attention.Prophylactic anticoagulant therapy can reduce the risk of VTE in patients with cancer.It is necessary to completely evaluate the benefits and potential adverse reactions and eliminate any contraindications of anticoagulant therapy before prophylactic anticoagulant therapy is administered to high-risk patients.
作者
马旭
王丹(综述)
韩森(审校)
Xu Ma;Dan Wang;Sen Han(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2020年第6期309-313,共5页
Chinese Journal of Clinical Oncology
基金
北京大学肿瘤医院科学研究基金项目(编号:2020自主-27)
北京市医院管理中心培育计划(编号:PG2020023)资助。
关键词
肿瘤相关静脉血栓栓塞症
血栓预防
低分子肝素
新型口服抗凝药
肿瘤心脏病学
cancer-associated venous thromboembolism
thrombosis prevention
low molecular weight heparin
new oral anticoagulants
onco-cardiology